Archive for the ‘United States’ Category
CEO took roundabout path to Emergent
By Marjorie Censer
Monday, January 3, 2011
Fuad El-Hibri has lived in all sorts of exotic locales, working for Citicorp in Saudi Arabia, consulting for Booz Allen Hamilton in Indonesia and establishing mobile telecommunications businesses in Russia, Venezuela and El Salvador.
But getting started in his current position as chief executive of Rockville-based pharmaceutical company Emergent BioSolutions took [...]
In: Chief Executive Officer, El-Hibri, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, U.S. Food and Drug Administration, United States, Yale university · Tagged with: Chief executive officer, DEPARTMENT OF HEALTH AND HUMAN SERVICES, El-Hibri, Emergent Biosolutions Inc, entrepreneur, Rockville
Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine
ROCKVILLE, Md., Dec 27, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. The product candidate, a third generation vaccine being developed [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration, United States · Tagged with: Anthrax vaccines, Clinical trial, Emergent BioSolutions, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services
Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology Meeting
ROCKVILLE, Md., Dec 06, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE: EBS) today announced the presentation of positive data from a Phase I dose escalation study of TRU-016 (Protocol 16007) at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida. In an oral presentation given yesterday, [...]
In: Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Hematology, Leukemia & Lymphoma Society, United States · Tagged with: American Society of Hematology, B-cell chronic lymphocytic leukemia, Emergent BioSolutions, Fuad El-Hibri, Hematology, Leukemia & Lymphoma Society, Non-Hodgkin lymphoma, Weill Medical College of Cornell University
Fuad El-Hibri and the International Biomedical Research Alliance
The International Biomedical Research Alliance (IBRA) is a philanthropic organization that is dedicated to the support of the NIH-Oxford-Cambridge Scholars Program, which strives to establish the highest standards of excellence in training biomedical researchers, advance groundbreaking biomedical research, enrich the pool of leaders in the field, and eliminate barriers which frustrate [...]
In: Anthrax vaccines, Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration, United States, Washington D.C · Tagged with: Education, Fuad El-Hibri, Leadership, Medical research, National Institutes of Health, Research, United States
Emergent BioSolutions Completes Acquisition of Trubion Pharmaceuticals
ROCKVILLE, Md., Oct 28, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the acquisition of Trubion Pharmaceuticals, Inc., following a majority vote to approve the merger by Trubion stockholders at a special meeting conducted at Trubion’s Seattle headquarters on October 28, 2010. The acquisition [...]
In: Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Seattle, Trubion Pharmaceuticals, United States · Tagged with: Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Seattle, Trubion Pharmaceuticals
Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine
ROCKVILLE, MD, September 17, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract, valued at up to $186.6 million, with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), for the development of a recombinant protective antigen [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration, United States · Tagged with: Anthrax vaccines, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Research and development, U.S. government
Emergent BioSolutions to Acquire Trubion Pharmaceuticals
Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity
Trubion offers novel, protein therapeutic platforms and scientific expertise for developing innovative therapeutic candidates
Transaction leverages large pharma partnerships to provide sales and marketing infrastructureidates
Emergent reaffirms 2010 guidance for revenues and net income
ROCKVILLE, Md., Aug 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. [...]
In: Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Shareholder, Trubion Pharmaceuticals, United States · Tagged with: Biosolutions, Board of directors, Common stock, Emergent BioSolutions, Seattle, Stock, Systemic Lupus Erythematosus, Trubion Pharmaceuticals
Emergent BioSolutions Hosts Biopreparedness Roundtable for NATO Parliamentarians
ROCKVILLE, Md., Jul 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE:EBS) is hosting “Bioterrorism Prevention, Preparedness and Response,” a forum organized for members of the North Atlantic Treaty Organization (NATO) Parliamentary Assembly (PA) to raise global awareness of the importance of biopreparedness. The visiting delegation [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, U.S. Food and Drug Administration, United States, Washington · Tagged with: Anthrax vaccines, Emergent BioSolutions, Food and Drug Administration, NATO, United States, United States Department of Health and Human Services
Fuad El-Hibri and Healthcare Reform
Fuad El-Hibri serves on the Advisory Board for the Yale Healthcare Conference, a joint effort between the Yale School of Management and the Health Professional Schools at Yale University. The 6th annual healthcare conference was held on April 9, 2010 in New Haven, CT. The conference topic was “Re-Forming Healthcare: Excellence in a Transforming [...]
In: Emergent Bioslutions, United States, Yale university · Tagged with: Colleges and Universities, Emergent BioSolutions, Fuad El-Hibri, Health care, United States, Yale university
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Recognized as Outstanding International Business Leader
ROCKVILLE, Md., Mar 11, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (EBS 15.96, -0.03, -0.19%) announced today that Fuad El-Hibri, its chairman and chief executive officer, has been named by the World Trade Center Institute (WTCI) as one of Maryland’s outstanding international business leaders. Celebrating the spirit of global ambition and excellence in international leadership, [...]
In: Business, Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, United States · Tagged with: Business, Emergent BioSolutions, Fuad El-Hibri, Maryland
